Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

HER2-expressing Cancers × ALX148 × 1 year × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Squamous Cell Carcinoma of Head and Neck 2 Neoplasm Metastasis 2 Head and Neck Neoplasms 2 Breast Neoplasms 2 Urinary Bladder Neoplasms 1 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Oropharyngeal Neoplasms 1 Lymphoma, Mantle-Cell 1 Lymphoma, Follicular 1 Lymphoma, B-Cell, Marginal Zone 1 HER2-expressing Cancers 1 Composite Lymphoma 1 Carcinoma, Transitional Cell 1

Interventions

zanidatamab 1 ALX148 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05027139 2025-10-16

A Study of Zanidatamab (ZW25) With Evorpacept (ALX148) in Patients With Advanced HER2-expressing Cancer

Jazz Pharmaceuticals

Phase 1/2 Completed

HER2-expressing Cancers

Data powered by HemOnc (CC BY 4.0) Colophon ⚡